BMT Investment Advisors lifted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,971 shares of the medical research company’s stock after buying an additional 500 shares during the period. BMT Investment Advisors’ holdings in Amgen were worth $2,317,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the stock. Carlton Hofferkamp & Jenks Wealth Management LLC raised its stake in shares of Amgen by 1.1% in the third quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 4,694 shares of the medical research company’s stock worth $933,000 after buying an additional 50 shares during the period. Independence Bank of Kentucky raised its stake in shares of Amgen by 3.5% in the third quarter. Independence Bank of Kentucky now owns 1,645 shares of the medical research company’s stock worth $318,000 after buying an additional 55 shares during the period. Carroll Financial Associates Inc. raised its stake in shares of Amgen by 0.8% in the second quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock worth $1,370,000 after buying an additional 58 shares during the period. Lincoln Capital Corp raised its stake in shares of Amgen by 0.3% in the second quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock worth $3,959,000 after buying an additional 58 shares during the period. Finally, Slow Capital Inc. raised its stake in shares of Amgen by 0.4% in the second quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock worth $2,543,000 after buying an additional 58 shares during the period. 76.33% of the stock is currently owned by institutional investors.
Several research analysts have recently commented on AMGN shares. Citigroup reaffirmed a “buy” rating on shares of Amgen in a research note on Monday, August 12th. Mizuho reaffirmed a “hold” rating and issued a $212.00 price objective on shares of Amgen in a research note on Sunday, September 29th. Piper Jaffray Companies raised their price objective on Amgen from $210.00 to $218.00 and gave the stock an “overweight” rating in a research note on Monday, August 26th. Cowen set a $231.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Sunday, September 29th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research note on Monday, September 30th. Eleven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $217.28.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter last year, the business posted $3.83 earnings per share. The firm’s revenue was down 3.1% on a year-over-year basis. On average, research analysts predict that Amgen, Inc. will post 14.33 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Investors of record on Friday, November 15th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a dividend yield of 2.86%. Amgen’s dividend payout ratio is currently 40.28%.
In other Amgen news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total transaction of $77,792.00. Following the completion of the transaction, the director now owns 16,336 shares in the company, valued at approximately $2,990,141.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $193.58, for a total value of $387,160.00. Following the transaction, the director now owns 16,436 shares of the company’s stock, valued at approximately $3,181,680.88. The disclosure for this sale can be found here. Insiders have sold a total of 17,851 shares of company stock valued at $3,671,900 in the last 90 days. 0.25% of the stock is currently owned by company insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Key terms to understand channel trading
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.